TCRX (TScan Therapeutics) Moat Score: 3/10 (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCRX TScan Therapeutics Inc TCRX
44 GF Score
Price $0.73
GF Value $1.32
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is TScan Therapeutics Moat Score?

TScan Therapeutics TCRX -3.15% 44 Moat Score is 3 as of Aug. 31, 2026. GuruFocus rates TCRX with a GF Score™ of 44/100 and a GF Value™ of $1.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,386 Biotechnology companies, TScan Therapeutics ranks better than 75.47% on this metric.

TScan Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

TScan Therapeutics has No Moat: TScan Therapeutics Inc operates in a competitive biotech industry with limited market share and no significant customer switching costs or brand strength, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes TScan Therapeutics might have No Moat - Very weak/transient advantages.

TScan Therapeutics  (NAS:TCRX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

TScan Therapeutics Moat Score Related Terms

TCRX vs MCRB, HYPD, ELOX: Moat Score Comparison

For the Biotechnology subindustry, TScan Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TScan Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Moat Score falls into.


TCRX
44GF Score
TScan Therapeutics Inc TCRX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
TScan Therapeutics (TCRX) has a Moat Score of 3 as of Aug. 31, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, TScan Therapeutics ranks #340 out of 1386 companies in the Biotechnology industry, placing it in the top 24.5%.
Is TScan Therapeutics' Moat Score too high?
TScan Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. TScan Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, TScan Therapeutics ranks #340 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Moat Score compare to MCRB and HYPD?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #340 out of 1386 companies for Moat Score. This places TScan Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. TScan Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TScan Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TScan Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Moat Score is 3 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TScan Therapeutics (TCRX) Overvalued in 2026?

Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued. The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32. GuruFocus considers TScan Therapeutics to be Possible Value Trap.

Key valuation signals for TCRX:

  • Moat Score: 3
  • GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
  • GF Score™: 44/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#340 of 1386)

No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TScan Therapeutics Business Description

Address 830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score

Get the complete analysis for TCRX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price
$1.32
GF Value